The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs

Journal of Virology

Volumn 83, Issue 8, 2009, Pages 3826-3833

  Ambrose, Zandrea ^a   Herman, Brian D ^a   Sheen, Chih Wei ^a   Zelina, Shannon ^a   Moore, Katie L ^d   Tachedjian, Gilda ^d,e   Nissley, Dwight V ^b,c   Sluis Cremer, Nicolas ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE TRIPHOSPHATE; HETERODIMER; LAMIVUDINE; PROTEIN P51; PROTEIN P66; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DRUG DERIVATIVE; NEVIRAPINE; PHOSPHONIC ACID DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DIMERIZATION; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; KINETICS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIOLOGICAL EXAMINATION; MISSENSE MUTATION; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENINE; ANTI-HIV AGENTS; DELAVIRDINE; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NEVIRAPINE; PHOSPHONIC ACIDS; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 64049111226     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01968-08     Document Type: Article

References (28)

1. Ambrose, Z., V. Boltz, S. Palmer, J. M. Coffin, S. H. Hughes, and V. N. Kewalramani. 2004. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78:13553-13561.
2. Baldanti, F., S. Paolucci, G. Maga, N. Labo, U. Hubscher, A. Y. Skoblov, L. Victorova, S. Spadari, L. Minoli, and G. Gerna. 2003. Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. AIDS 17:1568-1570.
3. Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234. (Pubitemid 23298217)
4. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367. (Pubitemid 30666686)
5. Feng, J. Y., and K. S. Anderson. 1999. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38:9440-9448.
6. Flys, T., D. V. Nissley, C. W. Claasen, D. Jones, C. Shi, L. A. Guay, P. Musoke, F. Mmiro, J. N. Strathern, J. B. Jackson, J. R. Eshleman, and S. H. Eshleman. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 192:24-29. (Pubitemid 40863853)
7. Gilleece, Y., C. Torti, S. Mandalia, B. G. Gazzard, D. Pillay, and A. L. Pozniak. 2003. The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients. HIV Med. 4:305-310.
8. Halvas, E. K., G. M. Aldrovandi, P. Balfe, I. A. Beck, V. F. Boltz, J. M. Coffin, L. M. Frenkel, J. D. Hazelwood, V. A. Johnson, M. Kearney, A. Kovacs, D. R. Kuritzkes, K. J. Metzner, D. V. Nissley, M. Nowicki, S. Palmer, R. Ziermann, R. Y. Zhao, C. L. Jennings, J. Bremer, D. Brambilla, and J. W. Mellors. 2006. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44:2612-2614.
9. Haubrich, R. H., C. A. Kemper, N. S. Hellmann, P. H. Keiser, M. D. Witt, D. N. Forthal, J. Leedom, M. Leibowitz, J. M. Whitcomb, D. Richman, and J. A. McCutchan. 2002. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 16:F33-F40.
10. Kosalaraksa, P., M. F. Kavlick, V. Maroun, R. Le, and H. Mitsuya. 1999. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol. 73:5356-5363. (Pubitemid 29274817)
11. Larder, B. A. 1992. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669.
12. Le Grice, S. F., C. E. Cameron, and S. J. Benkovic. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144.
13. Le Grice, S. F., and F. Gruninger-Leitch. 1990. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187:307-314. (Pubitemid 20040388)
14. Maier, G., U. Dietrich, B. Panhans, B. Schroder, H. Rubsamen-Waigmann, L. Cellai, T. Hermann, and H. Heumann. 1999. Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli: two tags tie it up. Eur. J. Biochem. 261:10-18. (Pubitemid 29166061)
15. Miranda, L. R., M. Gotte, F. Liang, and D. R. Kuritzkes. 2005. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob. Agents Chemother. 49:2648-2656. (Pubitemid 40917574)
16. Nissley, D. V., E. Halvas, D. Garfinkel, J. Mellors, and J. Strathern. 2003. Detection of rare drug-resistant HIV-1 reverse transcriptase variants using a sensitive phenotypic assay. Antivir. Ther. 8:S103.
17. Nissley, D. V., J. Julias, J. Mellors, S. Hughes, and J. Strathern. 2004. Detection and characterization of rare drug resistant HIV-1 RT variants using a sensitive phenotypic assay. Antivir. Ther. 9:S140.
18. Nissley, D. V., J. Radzio, Z. Ambrose, C. W. Sheen, N. Hamamouch, K. L. Moore, G. Tachedjian, and N. Sluis-Cremer. 2007. Characterization of novel nonnucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem. J. 404:151-157. (Pubitemid 46788095)
19. Olivares, I., A. Mulky, P. I. Boross, J. Tozser, J. C. Kappes, C. Lopez-Galindez, and L. Menendez-Arias. 2007. HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions. J. Mol. Biol. 372:369-381. (Pubitemid 47267958)
20. Selmi, B., J. Deval, K. Alvarez, J. Boretto, S. Sarfati, C. Guerreiro, and B. Canard. 2003. The Y181C substitution in 3′-azido-3′- deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′- deoxythymidine 5′-monophosphate-terminated primer. J. Biol. Chem. 278:40464-40472.
21. Shi, C., and J. W. Mellors. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41:2781-2785. (Pubitemid 27524761)
22. Shulman, N., A. R. Zolopa, D. Passaro, R. W. Shafer, W. Huang, D. Katzenstein, D. M. Israelski, N. Hellmann, C. Petropoulos, and J. Whitcomb. 2001. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 15:1125-1132.
23. Spence, R. A., W. M. Kati, K. S. Anderson, and K. A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
24. Svarovskaia, E. S., J. Y. Feng, N. A. Margot, F. Myrick, D. Goodman, J. K. Ly, K. L. White, N. Kutty, R. Wang, K. Borroto-Esoda, and M. D. Miller. 2008. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48:428-436.
25. Tachedjian, G., H. E. Aronson, M. de los Santos, J. Seehra, J. M. McCoy, and S. P. Goff. 2003. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J. Mol. Biol. 326:381-396.
26. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
27. Trkola, A., T. Ketas, V. N. Kewalramani, F. Endorf, J. M. Binley, H. Katinger, J. Robinson, D. R. Littman, and J. P. Moore. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-1885. (Pubitemid 28100739)
28. Xia, Q., J. Radzio, K. S. Anderson, and N. Sluis-Cremer. 2007. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci. 16:1728-1737. (Pubitemid 47195699)